AGN — Argenica Therapeutics Cashflow Statement
0.000.00%
- AU$32.11m
- AU$21.56m
- AU$0.51m
Annual cashflow statement for Argenica Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0 | 0.002 | 0.781 | 0.666 | 0.919 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.05 | -3.36 | -3.3 | -5.06 | -5.7 |
| Other Investing Cash Flow Items | — | — | -0.05 | 0.05 | 0 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | — | — | -0.05 | 0.05 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 7.85 | 5.13 | 3.73 | 11.6 | 0.347 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.8 | 1.77 | 0.375 | 6.62 | -5.36 |